Glial Fibrillary Acidic Protein (GFAP) was discovered by Amico Bignami and co-workers as a major fibrous protein of multiple sclerosis plaques. It was subsequently found to be a member of the 10nm or intermediate filament (IF) family, specifically the IF family Class III, which also includes peripherin, desmin and vimentin. GFAP is strongly and specifically expressed in astrocytes and certain other astroglia in the CNS, in satellite cells, peripheral ganglia, and in non-myelinating Schwann cells in peripheral nerves. In many damage and disease states GFAP expression is heavily upregulated in astrocytes. In addition, neural stem cells frequently strongly express GFAP. Point mutations in the protein coding region of the GFAP gene lead to Alexander disease which is characterized by the presence of abnormal astrocytes containing GFAP protein aggregates known as Rosenthal fibers .
ICC, IHC, WB
Synthetic peptide amino acids 411-422 (KTVEMRDGEVIK) of human GFAP (also known as Glial fibrillary acidic protein, accession number P14136); Rat: 100% identity (12/12 amino acids identical); Mouse: 100% identity (12/12 amino acids identical)
50% identity with other proteins (Vimentin, Desmin and Peripherin)
Human, Mouse, Rat
Store at ≤ -20 C for long term storage. For short term storage, store at 2-8 C. For maximum recovery of product, centrifuge the vial prior to removing the cap.
Does not cross-react with GFAP-R416W or other proteins (based on KO validation results)
Each new lot of this antibody is tested to confirm that it recognizes a single immunoreactive band of expected molecular weight when used to probe brain lysate.
These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.